Free Trial
NASDAQ:SPRY

ARS Pharmaceuticals Q1 2024 Earnings Report

ARS Pharmaceuticals logo
$15.49 +0.64 (+4.31%)
Closing price 04:00 PM Eastern
Extended Trading
$15.26 -0.23 (-1.52%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARS Pharmaceuticals EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.11
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

ARS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ARS Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
After Market Closes
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

ARS Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ARS Pharmaceuticals Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Cantor Fitzgerald Has Weak Estimate for SPRY FY2025 Earnings
Q2 EPS Estimate for ARS Pharmaceuticals Reduced by Analyst
Equities Analysts Set Expectations for SPRY Q2 Earnings
See More ARS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email.

About ARS Pharmaceuticals

ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

View ARS Pharmaceuticals Profile

More Earnings Resources from MarketBeat